Product Description
Mechanisms of Action: Voltage-Gated Calcium Channel Binder
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Pfizer
Company Location: NEW YORK NY 10017
Company CEO: Albert Bourla
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Generalized anxiety disorder|Depressive Disorder|Pregnancy Outcomes
Phase 2: Generalized anxiety disorder
Phase 1: Healthy Volunteers|Kidney Diseases|Generalized anxiety disorder|Other
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
2008-004443-11 | P3 |
Terminated |
Generalized anxiety disorder |
2012-01-03 |
|
2008-000761-32 | P3 |
Terminated |
Generalized anxiety disorder |
2010-02-25 |
|
ND | P3 |
Terminated |
Generalized anxiety disorder |
2010-01-09 |
|
2008-000763-42 | P3 |
Terminated |
Generalized anxiety disorder |
2009-09-25 |